C ombined measures of neurovascular and neurodegenerative features on magnetic resonance imaging (MRI) have recently been proposed to better characterize age-and stroke-related brain tissue damage. 1, 2 The total small vessel disease score was based on combinations of clinical visual scores, 1 and the brain health index was based on automated processing of several MRI sequences. 2 The total small vessel disease score has limited granularity and is prone to ceiling effects, whereas the brain health index requires high-resolution T1, T2, fluid attenuated inversion recovery, and T2 gradient echo sequences to be robust. These sequences may not always be available, particularly in studies using routine clinical imaging and in those designed to assess white matter hyperintensities (WMH) and other features of small vessel disease using visual ratings, where thicker MRI slices may have been obtained.
WMH volume and measures of atrophy, for example, cerebrospinal fluid (CSF) volume, may still be acquired from thicker slice images and only require fluid attenuated inversion recovery and T1 MRI. Individually, these volumes are related to vascular risk factor burden; however, vascular risk factors have been shown to explain little of their variance. 3, 4 Further, these volumes are related to cognitive impairment, but the relationship is often weak. 2, 5 It is unknown whether these individual volumes can be combined to better predict cognitive impairment.
Background and Purpose-Individual markers of cerebral small vessel disease and cerebral atrophy explain a small proportion of variance in vascular risk factors and cognitive function. Combining these markers into a single measure of neurovascular and neurodegenerative disease may be more powerful. We assessed this using data contained in the Virtual International Stroke Trials Archive -Prevention sub-archive. Methods-We extracted white matter hyperintensities (WMH) and cerebrospinal fluid (CSF) volumes from 317 people with ischemic stroke or transient ischemic attack who had baseline magnetic resonance imaging. We assessed progression of volumes in 208 people who had 2-year follow-up magnetic resonance imaging. WMH and CSF volumes were segmented from fluid attenuated inversion recovery and T1 images. The combined neurovascular and neurodegenerative measure was the sum of WMH and CSF volume normalized by intracranial volume. We assessed (1) the relationship between baseline vascular risk factors and imaging markers; and (2) the relationship between baseline imaging markers and MiniMental State Examination score at follow-up using multiple linear regression. We also assessed implications for sample size calculations using n=208 participants with follow-up magnetic resonance imaging. 
Results-Vascular

Methods
Participant and Data Extraction
Data were obtained from the Virtual International Stroke Trials Archive -Prevention sub-archive (http://virtualtrialsarchives.org/ vista). The Virtual International Stroke Trials Archive holds fully anonymized data from completed clinical trials, negating the need for local ethical approval. The project was approved by the Virtual International Stroke Trials Archive steering committee. We extracted baseline and 2-year follow-up MRI, Mini-Mental State Examination (MMSE) scores at 6 months (to limit confounding effects of stroke on cognition at baseline) and 2-year follow-up, and vascular risk factors at baseline, where available. Vascular risk factors included reported diagnosis of hypertension, hypercholesterolemia, diabetes mellitus, smoking, and atrial fibrillation and measured systolic and diastolic blood pressure. All data that we generated in this study will be made publicly available in the Virtual International Stroke Trials Archive, and requests for access can be made at http://virtualtrialsarchives.org/vista.
Brain MRI Acquisition and Processing
Brain MRI was acquired at baseline and 2-year follow-up; acquisition parameters are fully described in Table I in the online-only Data Supplement. The methods for WMH, CSF, and intracranial volume processing using T1 and fluid attenuated inversion recovery images have been described previously. 6 All volumes were visually verified, and WMH were checked and edited according to STRIVE guidelines (Standards for Reporting Vascular Changes on Neuroimaging). 7 WMH and CSF volumes were normalized (divided) by intracranial volume. The combined neurovascular and neurodegenerative MRI measure was simply the sum of normalized WMH and normalized CSF volume.
Statistical Analysis
All statistical analyses were performed using the Statistical Analysis System, version 9.4 (©2002-2012 SAS Institute, Inc). PROC REG was used to perform linear regression analyses between brain volumes, vascular risk factors, and MMSE using n=317 baseline participants. All regression β coefficients were standardized and compared with percentage differences calculated as ([β 1 −β 2 ]/β 1 )×100. PROC POWER was used for sample size calculations with brain volume progression data from n=208 participants. Sample size calculations were based on detecting reductions of 10% to 40% in the change from baseline to 2-year follow-up in each brain volume with power=0.8 and α=0.05.
Results
Participant Characteristics
Characteristics of all 317 participants at baseline, divided by those that had a useable follow-up MRI and those that did not, are in Table II in the online-only Data Supplement; n=208 participants had a useable follow-up MRI. Reasons for lack of a useable follow-up MRI included image artifact/motion and participant loss to follow-up. There were limited differences between participants who had a useable follow-up MRI and those who did not: death during study (a main reason for loss to follow-up) was higher in those without a follow-up MRI, and incidence of diabetes mellitus and diastolic blood pressure were higher in those with a follow-up MRI, as shown in Table II 
Prediction of 2-Year Follow-Up Cognition via Baseline Brain MRI Volumes
The association between 2-year follow-up MMSE, adjusted by MMSE at 6 months, and combined WMH and CSF volume (β=−0.219; P<0.0001) was 31% greater than WMH (β=−0.151; P=0.0005) and 11% greater than CSF (β=−0.194; P<0.0001) alone.
Changes in Individual and Combined Brain MRI Volumes and Sample Size Calculations
Changes in individual and combined brain MRI volumes in n=208 participants during the 2-year follow-up are in Table 1 . Sample size calculations based on these changes and hypothesized reductions (treatment effects) of between 10% and 40% are in Table 2 . Combined WMH and CSF volume had the greatest 2-year change effect size (Cohen's d, 0.35) and required between 207 and 3305 participants (20%) less per arm than WMH volume alone, depending on hypothesized treatment effect (Table 2) .
Discussion
We have shown that vascular risk factors explain over one-third more of the variance in a combined WMH and CSF volume measure than WMH alone. Further, this combined measure better predicted poststroke cognition than individual volumes. Furthermore, smaller sample sizes would be required to detect treatment effects in the combined measure compared with WMH and CSF alone. These results add to growing support for the use of combined brain damage metrics in stroke. 1, 2 WMH are often referred to as of presumed vascular origin; however, as with others, 3, 4 we found that multiple vascular risk factors explained a small proportion of variance in WMH. Although atrophy is often implicated in neurodegenerative rather than neurovascular conditions, 8 vascular risk factors explained approximately one-third more of the variance in
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CSF compared with WMH. Variance accounted for by vascular risk factors in the combined volume and CSF was similar. WMH volume had the weakest association with MMSE (compared with CSF volume and the combined WMH and CSF volume). This is consistent with previous work finding that WMH are more closely associated with individual cognitive domains rather than global cognitive function. 9 We will assess associations between the imaging markers used here and individual cognitive domains in the XILO-FIST trial (Xanthine Oxidase Inhibition for Improvement of LongTerm Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack). 6 WMH volume has previously been shown to reduce required sample sizes for clinical trials over cognitive scores. 10 Our estimates for sample sizes required in a WMH trial are consistent with recent results from the Mild Stroke Study in Edinburgh that based sample size calculations on a hypothetical treatment stabilizing and preventing progression of WMH. 11 The combined WMH and CSF measure developed here further reduced sample sizes required to detect hypothetical treatment effects by the low hundreds to several thousands, depending on effect size. However, even with a moderate treatment effect of 20%, the combined measure still required over 3000 participants per arm. Adding more tissue volumes or diffusion metrics to the combined brain damage measure may further reduce required sample sizes, and this will be assessed in future. Additionally, individual measures may be given different weights in a future combined metric rather than simply computing their sum.
Potential treatments for WMH and brain atrophy are currently being trialled, 6, 12 and the totality of our results (greater variance accounted for by vascular risk factors, stronger associations with cognition, and reduced sample size requirements) provides support for the use of a combined WMH and atrophy measure in early-phase studies designed to limit poststroke brain degradation and tackle vascular cognitive impairment.
Our work has limitations. Because we used data from clinical trials, there is the risk of confounding from relevant variables that were not assessed and limited generalizability to patients not well enough or motivated to take part in a trial. We obtained a limited battery of vascular risk factors that did not include, for example, physical activity, diet, and waist-hip ratio. However, we did acquire vascular risk factors that contribute to most of the population attributable risk of stroke. 13 One-third of participants did not have a useable follow-up MRI, and this limits the generalizability of our work to participants not well enough to return for a scan or lie still in the scanner at follow-up. However, these concerns are mediated by the limited differences between participants with and without useable follow-up MRI. WMH and CSF volumes required manual checking and editing, and this may limit application of our method to much larger samples. Several different scanners were used to acquire MRI; however, this replicates the reality of many clinical trials that are multisite. Further, interparticipant differences have long been shown to far outweigh interscanner differences, and our results are similar to single scanner studies. 3, 14 MMSE is a crude measure of global cognitive function, and this may not be sensitive to vascular cognitive impairment, which in turn may be more closely related to WMH. Additionally, we did not have assessments of cognition before stroke; therefore, we could not adjust for premorbid cognitive ability. Finally, further work is required to understand WMH regression and brain volume reduction because of a decrease in interstitial fluid, which may not have adverse clinical consequences.
Notwithstanding these limitations, we have provided a new combined neurovascular and neurodegenerative MRI measure in stroke that strengthened associations with clinical and cognitive parameters and reduced sample size requirements for prospective clinical trials. These results provide support for the use of a combined WMH and atrophy measure in earlyphase studies designed to assess the efficacy of treatments for brain degradation and cognitive impairment in stroke. CSF indicates cerebrospinal fluid; and WMH, white matter hyperintensity. *Treatment effects are hypothesized percentage reductions in change from baseline to 2-y follow-up between active treatment and control in each volume.
